EUVIMEDEUVIMED entdecken
Crossref

Repurposing aramchol as a therapeutic for dedifferentiated liposarcoma

Paul Dent, Michael Booth, Jane L. Roberts, Laurence Booth

Medical Research Archives · 2026

DOI: 10.18103/mra.2026.0679 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Paul Dent und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aramchol is an inhibitor of Stearoyl-CoA desaturase (SCD1), has anti-cancer properties, and concentrates in vivo in adipose tissues. Dedifferentiated liposarcoma, particularly when metastatic, has a dismal prognosis and novel therapeutic strategies are required. Aramchol interacted with the multi-kinase inhibitor regorafenib to kill liposarcoma cells, which was enhanced by the standard of care therapeutic agent doxorubicin. We compared the actions of the drugs upon isogenic primary diagnosis and recurrent liposarcoma cells. Regardless of primary or recurrent origin, doxorubicin killed cells to a similar extent. However, recurrent cells were significantly more sensitive to [aramchol plus regorafenib] and to [aramchol plus regorafenib plus doxorubicin] than primary cells. This was associated with greater activation of ATM, the AMPK and ULK1 and inactivation of AKT and mTORC1, resulting in higher levels of autophagosome formation. Knock down of either Beclin1 or ATG5 significantly reduced autophagosome formation and tumor cell killing. The highest levels of autophagosome formation and tumor cell killing required the induction of endoplasmic reticulum stress. In recurrent cells, knock down of eIF2A, regardless of signaling by ATM through the AMPK, prevented drug-induced increases in the expression of Beclin1, ATG5, BAX, BAK and BIM, and decreases in the levels of BCL-XL and MCL1. Our data support the use of aramchol as a novel therapeutic to be combined with standard-of-care drugs for dedifferentiated liposarcoma patients.

Zitieren

APA

Dent, P., Booth, M., Roberts, J. L., & Booth, L. (2026). Repurposing aramchol as a therapeutic for dedifferentiated liposarcoma. Medical Research Archives. https://doi.org/10.18103/mra.2026.0679

Vancouver

Dent P, Booth M, Roberts JL, Booth L. Repurposing aramchol as a therapeutic for dedifferentiated liposarcoma. Medical Research Archives. 2026. doi:10.18103/mra.2026.0679

BibTeX
@article{Dent2026,
  author = {Dent, Paul and Booth, Michael and Roberts, Jane L. and Booth, Laurence},
  title = {Repurposing aramchol as a therapeutic for dedifferentiated liposarcoma},
  journal = {Medical Research Archives},
  year = {2026},
  doi = {10.18103/mra.2026.0679}
}
Kostenlos starten →